Keyword: Biotechnology Industry Organization
As the drug pricing debate rolls on, biopharma lobbyists are staying busy. Very busy, in fact. PhRMA, for one, spent a record $29 million last year.
Pfizer's mature drugs plunged in China. AZ and GSK race their oral anemia drugs to Asia. Biotech leaders worry IP crackdown will hurt collaboration.
During the second Democratic debate last week, Sen. Bernie Sanders predicted healthcare industry ads during CNN commercial breaks. He wasn’t wrong.
The biotech group wants 50% of biotech's senior leaders to be women by 2025, and it'll consider expelling companies that don't play along.
Pharma has suffered another defeat in the state-by-state war over drug prices.
A Nevada judge denied the drug industry's request for an injunction that would have stopped a new pricing-disclosure law in its tracks.
Top industry lobby groups are challenging a new drug pricing law in Nevada.
Even without U.S. tax reforms expected to spur M&A action, biopharma dealmaking hasn’t slowed down, and nor should industry watchers assume it will.
Executives are worried, big time, with 88% pegging the issue as their biggest challenge.
Marathon’s Emflaza pricing remains in an unwelcome spotlight as eight more senators zero in on the company and its newly approved, $89,000 DMD med.